Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer

Journal of Cranio-Maxillofacial Surgery

Volumn 36, Issue 2, 2008, Pages 89-94

  Ervens, Juergen ^a   Fuchs, Hendrik ^a   Niemann, Volker Till ^a   Hoffmeister, Bodo ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

oral squamous cell carcinoma; pyruvate kinase; screening test; TuM2 PK

Indexed keywords

EDETIC ACID; MONOCLONAL ANTIBODY; PYRUVATE KINASE; PYRUVATE KINASE ISOENZYME M 2; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER DIAGNOSIS; CANCER PATIENT; CANCER TISSUE; CLINICAL EXAMINATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDICAL INSTRUMENTATION; MOUTH CARCINOMA; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CLINICAL ENZYME TESTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOLYSIS; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PYRUVATE KINASE; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 39649112383     PISSN: 10105182     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcms.2007.08.006     Document Type: Article

References (35)

1. Bena-Boupda N.F., Rezai S.S., Klett R., Eigenbrodt E., and Bauer R. Value of tumor M2-PK in thyroid carcinoma: a pilot study. Anticancer Res 23 (2003) 5237-5240
2. Brinck U., Eigenbrodt E., Oehmke M., Mazurek S., and Fischer G. L- and M2-pyruvate kinase expression in renal cell carcinomas and their metastases. Virchows Arch 424 (1994) 177-185
3. Eigenbrodt E., Kallinowski F., Ott M., Mazurek S., and Vaupel P. Pyruvate kinase and the interaction of amino acid and carbohydrate metabolism in solid tumors. Anticancer Res 18 (1998) 3267-3274
4. Ewald N., Toepler M., Akinci A., Kloer H.U., Bretzel R.G., and Hardt P.D. Pyruvatkinase M2 (Tumor M2-PK) im Stuhl als Screeningparameter für kolorektale Neoplasien. Eine Übersicht über bisher publizierte Daten. Z Gastroenterol 43 (2005) 1313-1317
5. Field E.A., Morrison T., Darling A.E., Parr T.A., and Zakrzewska J.M. Oral mucosal screening as an integral part of routine dental care. Br Dent J 179 (1995) 262-266
6. Hardt P.D., Ngoumou B.K., Rupp J., Schnell-Kretschmer H., and Kloer H.-U. Tumor M2 pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer. Anticancer Res 20 (2000) 4965-4968
7. Hardt P.D., Mazurek S., Toepler M., Schlierbach P., Bretzel R.G., Eigenbrodt E., and Kloer H.U. Faecal tumor M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer 91 (2004) 980-984
8. Hegele A., Varga Z., Kosche B., Stief T., Heidenreich A., and Hofmann R. Pyruvate kinase type M2 in urological malignancies. Urol Int 70 (2003) 55-58
9. Howaldt H.P., Vorast H., Blecher J.C., Reicherts M., and Kainz M. Ergebnisse aus dem DÖSAK-Tumorregister. Mund Kiefer Gesichtschir 4 Suppl. 1 (2000) S216-S225
10. Kaura B., Bagga R., and Patel F.D. Evaluation of the pyruvate kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma. J Obstet Gynaecol Res 30 (2004) 193-196
11. Koss K., Harrison R.F., Gregory J., Darnton S.J., Anderson M.R., and Jankowski J.A.Z. The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplastic-dysplasia-adenocarcinoma sequence in Barrett's oesophagus. J Clin Pathol 57 (2004) 1156-1159
12. Lueftner D., Mesterharm J., Akrivakis C., Geppert R., Petrides P.E., Wernecke K.-D., and Possinger K. Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res 20 (2000) 5077-5082
13. Mazurek S., Grimm H., Oehmke M., Weisse G., Teigelkamp S., and Eigenbrodt E. Tumor M2-PK and glutaminolytic enzymes in the metabolic shift of tumor cells. Anticancer Res 20 (2000) 5151-5154
14. Mazurek S., Boschek C.B., Hugo F., and Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 15 (2005) 300-308
15. McDowell G., Gupta S., Dellerba M., Coppinger T., Levy R.D., and Keevil B.G. Plasma concentrations of tumour dimeric pyruvate kinase are increased in patients with chronic cardiac failure. Ann Clin Biochem 41 (2004) 491-493
16. Murphy M.M., Marsillach J., Camps J., Fernández-Ballart J., Mackness B., Mackness M., Ferré N., and Joven J. Tumor M2 pyruvate kinase as a stool marker for colorectal cancer: stability at room temperature and implications for application in the screening setting. Clin Chem 52 (2006) 781-782
17. Oremek G.M., Teigelkamp S., Kramer W., Eigenbrodt E., and Usadel K.-H. The pyruvate kinase isoenzyme tumor Me (Tu M2-PK) as a tumor marker for renal carcinoma. Anticancer Res 19 (1999) 2599-2602
18. Oremek G.M., Sapoutzis N., Kramer W., Bickeboeller R., and Jonas D. Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma. Anticancer Res 20 (2000) 5095-5098
19. Oremek G.M., Gerstmeier F., Sauer-Eppel H., Sapoutzis N., and Wechsel H.W. Pre-analytical problems in the measurement of tumor type pyruvate kinase (tumor M2-PK). Anticancer Res 23 (2003) 1127-1130
20. Oremek G.M., Rox S., Mitrou P., Sapoutzis N., and Sauer-Eppel H. Tumor M2-PK levels in haematological malignancies. Anticancer Res 23 (2003) 1135-1138
21. Oremek G.M., Rutner F., Sapoutzis N., and Sauer-Eppel H. Tumor marker pyruvate kinase type tumor M2 in patients suffering from diabetic nephropathy. Anticancer Res 23 (2003) 1155-1158
22. Perkins G.L., Slater E.D., Sanders G.K., and Prichard J.G. Serum tumor markers. Am Fam Physician 15 (2003) 1075-1082
23. Rijksen G., van der Heijden M.C.M., Oskam R., and Staal G.E.J. Subunit-specific phosphorylation of pyruvate kinase in medullary thyroid carcinomas of the rat. FEBS Lett 233 (1988) 69-73
24. Roigas J., Deger S., Schroeder J., Wille A., Turk I., Brux B., Jung K., Schnorr D., and Loening S.A. Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma. Urol Res 31 (2003) 358-362
25. Schneider J., and Schulze G. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Anticancer Res 23 (2003) 5089-5093
26. Schneider J., Velcovsky H.-G., Morr H., Katz N., Neu K., and Eigenbrodt E. Comparison of the tumor markers tumor M2-PK, CEA, CYRFA 21-1, NSE and SCC in the diagnosis of lung cancer. Anticancer Res 20 (2000) 5053-5058
27. Schneider J., Neu K., Velcovsky H.-G., Morr H., and Eigenbrodt E. Tumor M2-pyruvate kinase in the follow-up of inoperable lung cancer patients: a pilot study. Cancer Lett 193 (2003) 91-98
28. Schulze G. The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer. Anticancer Res 20 (2000) 4961-4964
29. In: Sobin L.H., and Wittekind C. (Eds). TNM classification of malignant tumours. 6th ed. (2002), Wiley-Liss
30. Staib P., Hoffmann M., and Schinkoethe T. Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors. Clin Chem Lab Med 44 (2006) 28-31
31. Ugurel S., Bell N., Sucker A., Zimpfer A., Rittgen W., and Schadendorf D. Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma. Int J Cancer 117 (2005) 825-830
32. Varga Z., Hegele A., Stief T., Heidenreich A., and Hofmann R. Determination of pyruvate kinase type tumor M2 in human renal cell carcinoma: a suitable tumor marker?. Urol Res 30 (2002) 122-125
33. Ventrucci M., Cipolla A., Racchini C., Casadei R., Simoni P., and Gullo L. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer. Dig Dis Sci 49 (2004) 1149-1155
34. Vogel T., Driemel C., Hauser A., Hansmann A., Lange S., Jonas M., and Moslein G. Vergleich verschiedener Stuhltests zur Detektion von Neoplasien des Kolon. Dtsch Med Wochenschr 130 (2005) 872-877
35. Zhang B., Chen J.Y., Chen D.D., Wang G.B., and Shen P. Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls. World J Gastroenterol 10 (2004) 1643-1646